Real World Evidence (RWE)
RWE describes evidence relating to patient health or experience or care delivery collected in the ‘real world’, i.e. outside of controlled research studies. The quality of RWE varies widely and its use is not consistently accepted but it has the potential to reduce uncertainty and improve decision-making.
Data Governance Arrangements for Real-World Evidence: South Korea
1 September 2017
In 2015, OHE published a report which set out the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to generate Real-World Evidence (RWE), thereby working toward a set of “international standards”1.
Incentives for New Drugs to Tackle Anti-Microbial Resistance
1 May 2017
Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage…
Data Governance Arrangements for Real-World Evidence
1 November 2015
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is…
Dementia: The R&D Landscape
1 November 2015
This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health.
Exploring the Interdependencies of Research Funders in the UK
1 July 2014
As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their…
The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
1 April 2014
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen,…
The R&D Cost of a New Medicine
1 December 2012
The cost of R&D for a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because…
Is There a Productivity Crisis in Pharmaceutical R&D?
6 January 2012
This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar. It focuses primarily on…
Summary Report of the OHE/EFPIA Antibacterial Roundtable
1 November 2011
Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures…